Purchase this article with an account.
J. G. Guzman, E. Lopez, F. Martinez, T. Valdez; Utility of Bevacizumab (avastin®) for the Management of Ocular Inflammatory Illnes Complications. Invest. Ophthalmol. Vis. Sci. 2007;48(13):275.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate utility and safety of the use of Intravitreal Bevacizumab for the treatment of ocular inflamatory illness complications.
we applied 1.87mg of intravitreal Bevacizumab for the treatment of ocular inflammatory illness complications, and evaluated patient's clinical course, BCVA and complications at 1,7,30 and 90 days after the intravitreal injection.
We included 8 eyes of 7 patients, 1 male and 6 female, with an average age of 20 years, 2 eyes with Cystoid Macular Edema (1 secondary to Pars Planitis and 1 secondary to HLAB27 (+) anterior uveitis), 2 eyes with rubeosis iridis (both secondary to Vogt-Koyanagi-Harada disease), 2 eyes with coroidal neovascularisation (1 secondary to Toxoplasmosis and 1 secondary to Inner Punctate Choroiditis), 1 eye with Branch Retinal Arterial Occlusion (secondary to Wegener's Granulomatosis) and 1 eye with neovascularisation of the peripherial retina (secondary to Pars Planitis).We observed improvement on clinical course and BCVA in all patients treated, and we did not find any complication associated with the use of intravitreal bevacizumab.
We concluded that the use of intravitreal bevacizumab is useful and safe in the management of ocular inflammatory illness complications. We need a longer study and to include more patients to prove its utility and safety
Hospital Nuestra Señora de la Luz I.A.P. Mexico
This PDF is available to Subscribers Only